PROCEPT BioRobotics ® (Nasdaq: PRCT) today highlighted the latest update to the European Association of Urology (EAU) Guidelines for male lower urinary tract symptoms (LUTS), which include an upgrade ...

Results with Optilume consistent in clinical trials and real world, regardless of prostate ...

Image courtesy of Prodeon Medical] Prodeon Medical announced today that it received FDA 510(k) clearance for its Urocross ...

Canine benign prostatic hyperplasia (BPH) is a common, age‐related condition in intact male dogs, characterised by a non‐malignant enlargement of the prostate gland. Typically emerging in middle-aged ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

Extracts of the berries of saw palmetto, a small palm tree native to the southeastern U.S., are used widely to treat benign prostatic hyperplasia (BPH). In this randomized trial conducted in ...

In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score ...

Benign prostatic hyperplasia (BPH) is a prevalent condition characterised by the non-malignant enlargement of the prostate gland, which frequently precipitates lower urinary tract symptoms (LUTS).

Results indicate preservation of sexual function. (HealthDay News) — Blue laser vaporization alleviates lower urinary tract symptoms while preserving sexual function in patients undergoing benign ...

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for ...

PHILADELPHIA (WPVI) -- Benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate gland, is the most common benign tumor found in men. BPH produces symptoms by obstructing the flow ...